Talphera

CA - San MateoBiotechnology

Website LinkedIn Careers Page

Focus: Oral-Transmucosal Drug Delivery

Talphera is a life sciences company focused on Oral-Transmucosal Drug Delivery.

Oncology Nephrology

Profile data last refreshed Yesterday

Open Jobs

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

7 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Niyad

Acute Kidney Injury

N/A

Clinical Trials (1)

NCT06150742Nafamostat Efficacy in Phase 3 Registrational CRRT Study

N/A

Help build intelligence for Talphera

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Single dose of SUF NT 15 mcg

Plasma Concentrations

Phase 1

Clinical Trials (1)

NCT01761565Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab

Phase 1

Treatment Arm A: Sufenta®

Healthy

Phase 1

Clinical Trials (1)

NCT02082236Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects

Phase 1

Sufentanil NanoTab

Pharmacokinetics

Phase 1

Clinical Trials (1)

NCT01721070Effect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics

Phase 1

Treatment A: Sufentanil IV

Pharmacokinetics

Phase 1

Clinical Trials (1)

NCT01639729Effect of Delivery Route on PK of Sufentanil NanoTab

Phase 1

Sublingual Sufentanil/Triazolam NanoTab™

Sedation

Phase 2

Clinical Trials (1)

NCT00894699A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure

Phase 2

Sublingual sufentanil NanoTabs™ and placebo NanoTabs™

Cancer

Phase 2

Clinical Trials (1)

NCT00833040A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain

Phase 2

Sufentanil NanoTab PCA System/15 mcg

Pain, Postoperative

Phase 2

Clinical Trials (1)

NCT00859313An Open-Label Functionality, Safety and Efficacy Study in Patients Undergoing Elective Unilateral Knee Replacement

Phase 2

Sufentanil NanoTab

Post Operative Pain

Phase 2

Clinical Trials (1)

NCT00612534A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Elective Unilateral Total Knee Replacement

Phase 2

Oral sufentanil

Major Upper or Lower Abdominal Surgery

Phase 2

Clinical Trials (1)

NCT00718081A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Major Abdominal Surgery

Phase 2

Sufentanil NanoTab 20 mcg

Acute Pain

Phase 2

Clinical Trials (1)

NCT01710345Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy

Phase 2

Sufentanil NanoTab PCA System/15 mcg

Post-Operative Pain

Phase 3

Clinical Trials (1)

NCT01539538A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain

Phase 3

sufentanil sublingual 30 mcg tablet

Moderate-to-severe Acute Pain

Phase 3

Clinical Trials (1)

NCT02447848Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain

Phase 3

Sufentanil NanoTab PCA System/15 mcg

Post-Operative Pain

Phase 3

Clinical Trials (1)

NCT01539642A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery

Phase 3

Sufentanil NanoTab PCA System/15 mcg

Post Operative Pain

Phase 3

Clinical Trials (1)

NCT01660763Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement Surgery

Phase 3

Zalviso™ 15 mcg

Moderate-to-severe Acute Pain

Phase 3

Clinical Trials (1)

NCT02662764Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg

Phase 3

sufentanil sublingual tablet 30 mcg

Acute Moderate-to-severe Pain

Phase 3

Clinical Trials (1)

NCT02662556A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain

Phase 3

Sufentanil Tablet 30 mcg

Post-Operative Pain

Phase 3

Clinical Trials (1)

NCT02356588A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery

Phase 3